Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
10-Q
Rhea-AI Filing Summary
Selectis Health, Inc. (GBCS) reported Q2 2026 results showing a sharp shift driven by asset sales and balance sheet repair. For the three months ended June 30, 2026, healthcare revenue fell to $4.6 million from $10.4 million, mainly due to selling four Georgia facilities. Despite lower operating scale, a $10.2 million gain on the May sale of two Georgia facilities and prior January sales produced net income of $8.1 million for the quarter and $14.6 million for the first half, versus losses in 2025. Basic EPS was $2.65 for the quarter and $4.77 year-to-date.
Total debt (net of discount) decreased to $17.0 million from $31.0 million, and stockholders’ position moved from a $(6.6) million deficit at December 31, 2025 to positive equity of $8.0 million at June 30, 2026, supported by asset sale gains and debt paydowns. Cash, cash equivalents and restricted cash increased to $7.9 million, aided by $28.9 million of Georgia sale proceeds, but operating cash flow was negative $4.3 million for the first half.
Management states that substantial doubt exists about the company’s ability to continue as a going concern due to historical losses and projected cash needs. The company discloses continuing material weaknesses in internal control over financial reporting. On June 22, 2026, Selectis entered into a Merger Agreement under which a subsidiary of Black Pearl Equities II, LLC will launch a cash tender offer to acquire all outstanding common shares at $5.75 per share, subject to a 70% minimum tender and other conditions, followed by a cash merger.
Positive
- Debt reduced to $17.0 million from $31.0 million (net of discount) by June 30, 2026, mainly through mortgage and note payoffs tied to Georgia facility sales, significantly deleveraging the balance sheet.
- Equity swung from a $(6.6) million deficit to $8.0 million positive between December 31, 2025 and June 30, 2026, driven by gains on asset sales and debt reduction.
- Net income of $14.6 million for the first half of 2026, versus a $1.0 million loss in the prior-year period, largely from $19.0 million of gains on sale of four Georgia facilities.
- A Merger Agreement provides for a $5.75 per share cash tender offer for all outstanding GBCS common stock, with a subsequent cash merger if closing conditions, including a 70% minimum tender, are met.
Negative
- Healthcare revenue declined 56% in Q2 2026 and 44% for the first half year-over-year, reflecting the loss of four Georgia facilities and a smaller operating base.
- Management discloses that substantial doubt exists about Selectis Health’s ability to continue as a going concern, citing historical losses, low working capital of about $0.2 million, and projected cash needs.
- Operating activities used $4.3 million of cash in the first half of 2026, indicating that underlying operations are not funding themselves despite reported net income from asset sales.
- The company reports material weaknesses in internal control over financial reporting, including deficiencies in review processes and accounting for complex equity instruments, which were not remediated by June 30, 2026.
